Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dario Cubides

Physician Assistant Rancho Viejo, TX Physician Assistant

NPI 1366878530 CMS profile 10825099

809 Tesoro Ave Ste E, Rancho Viejo, TX 78575

Open in the dashboard

General payments

$8,603

532 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dario Cubides of Rancho Viejo, TX is reported in the CMS Open Payments database as having received $8,603 across 532 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,715 82
2024 General $1,495 105
2023 General $1,653 107
2022 General $1,824 120
2021 General $1,916 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dario Cubides
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Dario Cubides were reported at $1,715. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Dario Cubides Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,916 $132 $37–$438 $132
2022 $1,824 $155 $48–$522 $149
2023 $1,653 $167 $52–$557 $160
2024 $1,495 $178 $55–$600 $164
2025 $1,715 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,951 144 payments
  2. Amgen Inc. $1,359 97 payments
  3. Lilly USA, LLC $1,339 75 payments
  4. Merck Sharp & Dohme Corporation $492 30 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $350 21 payments
  6. Novartis Pharmaceuticals Corporation $340 27 payments
  7. Amarin Pharma Inc. $305 20 payments
  8. Dexcom, Inc. $279 10 payments
  9. Astellas Pharma US Inc $274 12 payments
  10. AstraZeneca Pharmaceuticals LP $258 12 payments
  11. Other $1,657 84 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,503 531 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $1,609 122 payments
  2. Ozempic $1,316 116 payments
  3. Otezla $1,056 73 payments
  4. MOUNJARO $970 59 payments
  5. Repatha Cardiology $633 50 payments
  6. VERQUVO $448 25 payments
  7. Kerendia $350 21 payments
  8. REPATHA Cardiovascular $313 23 payments
  9. STEGLATRO $312 20 payments
  10. ZEPBOUND $305 15 payments
  11. Other $5,270 324 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

4,295

Median for Physician Assistant: 241

Drug cost

$1,075,097

Median for Physician Assistant: $4,110

Branded share of claims

24.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 152 $225,705
Mounjaro Tirzepatide Brand 115 $170,248
Farxiga Dapagliflozin Propanediol Brand 85 $104,066
Rybelsus Semaglutide Brand 39 $87,345
Vascepa Icosapent Ethyl Brand 95 $75,837
Jardiance Empagliflozin Brand 49 $65,133
Kerendia Finerenone Brand 42 $60,205
Icosapent Ethyl Generic 81 $40,773
Tradjenta Linagliptin Brand 26 $36,140
Januvia Sitagliptin Phosphate Brand 23 $32,893

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $292
$292 115 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $235
$235 42 —
VERQUVO
  • Merck Sharp & Dohme Corporation $115
$115 — —
Otezla
  • Amgen Inc. $85
$85 — —
Repatha
  • Amgen Inc. $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

532 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record